Summary — Putting It All Together for 1L EGFRm NSCLC

Dr. Nagasaka closes the program with a four-part summary of subcutaneous amivantamab Q4W plus lazertinib in the first-line setting for EGFR-mutated advanced NSCLC. On efficacy, she revisits the MARIPOSA data: median overall survival not reached versus 36.7 months with osimertinib (HR, 0.75; P=.005), median progression-free survival of 23.7 versus 16.6 months (HR, 0.70; P<.001), overall response rates of 86% versus 85%, NCCN category 1 preferred status, and a higher 36-month on-treatment rate. She reframes these data as supporting an expectation that, with proactive supportive care, most patients can be encouraged to remain on therapy.

On CNS outcomes, Dr. Nagasaka highlights the MARIPOSA brain metastases subgroup: intracranial progression-free survival of 25.4 versus 22.2 months (HR, 0.79), intracranial duration of response of 35.7 versus 29.6 months, and a doubling of the 36-month intracranial PFS rate (36% vs 18%). Protocol-mandated serial MRIs in all participants underpin the reliability of these data, and category 1 preferred status applies regardless of CNS involvement. On safety and tolerability, she reiterates that only 8% of cohort 5 patients discontinued all study treatment because of treatment-related adverse events, that the adverse event peak in months 1 through 4 is followed by a predictable decline, and that the COCOON regimen and prophylactic anticoagulation support persistence on therapy. On delivery, she notes the approximately 5-minute administration time, the 80% reduction in administration-related reactions versus the intravenous formulation, and the reduction from 26 to 13 annual visits with Q4W dosing while preserving the MARIPOSA efficacy benchmark.

Thank you for watching this Cancer Network Between the Lines program on subcutaneous amivantamab Q4W plus lazertinib in first-line EGFR-mutated advanced NSCLC. Please subscribe to our e-newsletter for information on upcoming video series.